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a b s t r a c t
Background: Overall incidence and geographic range of Tick-borne Encephalitis (TBE), a vaccine pre-
ventable infection, have steadily increased in Switzerland over the last 50 years. While fully subsidized
vaccination has been recommended in many areas for well over a decade, vaccine coverage and variables
associated with vaccination compliance among Swiss adults are poorly understood.
Methods: In 2018 we conducted a national, cross-sectional survey of vaccination cards evaluating TBE
vaccination coverage and compliance among adults (18-79) in Switzerland.
Results: Nationwide TBE vaccination coverage was 41.7% (range 14.3% to 60.3%) for 1 dose and 32.9%
(range 8.4% to 50.4%) for a complete primary series (3 doses). There was a significant correlation between
average disease incidence by canton (2009-2018) and vaccine coverage at both 1 and 3 doses. Of the over-
all population, 9.5% had received at least one TBE booster vaccination with large regional coverage vari-
ation. We estimated that 23% of adults in Switzerland would be protected from infection based on their
vaccination history and 135 (95% CI: 112-162) TBE cases were prevented in 2018. Individuals reporting
previous experience with tick-associated health problems, those frequently in nature or those with
‘‘high” perceived risk of contracting TBE, were significantly more likely to have received at least one vac-
cine dose, indicating a positive impact of awareness on vaccination compliance. We also calculated a TBE
incidence rate of 6.83/100,000 among the unvaccinated adult population in Switzerland and estimated
vaccine effectiveness at 91.5% (95% CI: 90.9-92.0%).
Conclusions: These findings provide an important reference for TBE vaccination levels in Switzerland and
further suggest that public health interventions promoting knowledge of TBE health impacts and risk fac-
tors may be beneficial in improving TBE vaccination coverage but should be tailored to account for
heterogeneity in vaccine uptake.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under theCCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Tick-borne Encephalitis (TBE) is a serious viral infection of the
Central Nervous System which can result in severe disease, perma-
nent disability, and death. The causative agent of TBE, the Tick-
borne Encephalitis Virus (TBEV), is widespread throughout Russia,
parts of Asia, the Baltic states, southern Sweden and Finland and a
large part of Central Europe [1,2]. TBE was first described in
Switzerland in 1969 and has, over the last 50 years, become
endemic, spreading from the north-eastern part of the country pro-
gressively west and southward [3–5]. Switzerland is now among
the most affected countries in Central Europe and, in 2018, the
average disease incidence reached 4.37 cases/100,000 individuals
– just short of the World Health Organization (WHO) definition
of  5.0 cases/100,000 as ‘‘highly endemic” [6,7]. Incidence, how-
ever, is not homogenous. In both Switzerland and in other affected
countries, disease generally occurs in geographically-localized
areas where TBEV circulates between local tick vector and small
mammal reservoir populations. Additionally, incidence is higher
among men compared to women and among individuals from 60
to 79 compared to other age groups [6].
Currently, two TBE vaccines (FSME-Immun; Pfizer and Encepur;
Bavarian Nordic) are licensed in Europe and available in Switzer-
land. Conventional primary vaccination is a series of 3 immuniza-
tions administered over 6–15 months, depending on vaccine type.
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Both vaccines elicit viral neutralizing antibody responses which are
thought to protect from infection. Complete primary vaccination
results in antibody responses which persist for many years. To
maintain titres, both manufacturers recommend an initial booster
3 years after completion of the primary series, and every 5 years
until age 50 for Encepur and 60 for FSME-Immun, then every
3 years thereafter [8–10]. In Switzerland, however, a simplified
scheme has been adopted with boosters beginning every 10 years
after completion of the primary series regardless of age [11].
The Swiss Confederation is composed of 26 semi-autonomous
cantons. Vaccination recommendations are made by the FOPH
and are adopted at the cantonal level. While health insurance is
privatized in Switzerland, all individuals are required to be cov-
ered, and FOPH-recommended vaccinations are reimbursed.
Although TBE vaccination was previously available to individuals
at personal expense, in 2006 the FOPH officially recommended
TBE vaccination of all individuals from the age of 6 residing or
spending significant time in TBEV risk areas within Switzerland,
areas with 3 or more diagnosed cases of TBE or areas where TBEV
has been found circulating in local tick populations [12]. The orig-
inal recommendation included roughly 71 municipalities (of 2,212
total) in 15 Swiss cantons and has been periodically updated and
expanded by the FOPH based on disease monitoring efforts
through the comprehensive mandatory infectious disease report-
ing system. This system utilizes defined clinical and laboratory cri-
teria for TBE infection and is in place in Switzerland since 1988
(https://www.ecdc.europa.eu/en/publications-data/country-pro-
file-switzerland-tick-borne-encephalitis-tbe). Despite these rec-
ommendations, however, TBE incidence has continued to
increase and, as a result, the FOPH dramatically expanded its rec-
ommendation in 2019 to include all Swiss cantons, with the excep-
tions of the cantons of Geneva (45 municipalities; 5.8% of the 2018
Swiss population) and Ticino (115 municipalities; 4.1% of the 2018
Swiss population), as risk areas [13]. Significantly, this increase in
TBE disease incidence occurred even in cantons where vaccination
was specifically recommended and reimbursed by compulsory
health insurance, suggesting poor vaccine uptake among those at
risk.
While TBE vaccination has been FOPH-recommended and reim-
bursed by compulsory health insurance in many areas for more
than a decade, the overall level of vaccine coverage isn’t known.
Switzerland does not have a national, population-based immuniza-
tion registry system and vaccination coverage among adults is not
otherwise routinely monitored. Regional variations in coverage
and how they relate to disease incidence and vaccination recom-
mendations further remain unclear. In addition, individual-level
variables impacting TBE vaccination compliance are incompletely
understood. Understanding the frequency and distribution of vac-
cinated individuals can help to estimate the percentage of the adult
population that is protected against TBE and may further have
important impacts on the design of vaccination strategies and dis-
ease control. To address these knowledge gaps, we conducted a
national survey evaluating TBE vaccination coverage and compli-
ance among adults in Switzerland.
2. Methods
2.1. Study design
In collaboration with the Swiss FOPH and all 26 cantons since
1999, we have developed a robust system to monitor routine vac-
cination coverage in children aged 2, 8 and 16 years at the national
and cantonal levels based on obtaining vaccination records by mail
[14]. Therefore, to estimate the breadth and depth of TBE vaccina-
tion coverage among adults in Switzerland, we used a similar
methodology to perform a national, cross-sectional study, where
randomly selected adults aged 18–79 were requested by mail to
submit a copy of their vaccination record. In addition, to assess
knowledge of TBE infection, risk behaviours, and reasons for
receiving or abstaining from vaccination, participants were further
asked to complete a short questionnaire.
2.2. Selection and recruitment of participants
A comprehensive list of all individuals with a registered mailing
address in Switzerland was provided by an external organization
(Institute for Social Research, Zurich, Switzerland). This list was
divided by the 7 statistical ‘‘large regions” defined by the Swiss
Federal Statistical Office ((SFSO), Supplementary Table 1), and the
population of each region was further divided into three age
groups: 18–39, 40–59 and 60–79. From each region and age group,
disproportional stratified random sampling was used to select
1,280 individuals invited to participate, for a total sample size of
26,880 (1,280  7 regions  3 age groups).
Potential participants were contacted by mail beginning in
February 2018. To participate, individuals were requested to sub-
mit a copy of their vaccination record and to complete a short
questionnaire. Non-responders received a single reminder letter
in May 2018. As Switzerland is a multilingual country, the lan-
guage (German, French or Italian) of both the letter and question-
naire were matched to the official language of the municipality of
each address. The total enrolment period was from February to
October 2018. Participants submitting a completed questionnaire,
a vaccination record, or both, were eligible for a lottery to receive
one of three 1,000 CHF ($1,065) cash prizes with individuals sub-
mitting both a completed questionnaire and a copy of their vacci-
nation record entered twice.
2.3. Data collection
2.3.1. Vaccination records
Both paper-based forms and private digital vaccination records
(i.e. healthcare provider or meineimpfungen.ch) are used in
Switzerland. Vaccination records contain dates of vaccination, vac-
cine names and lot numbers that are manually recorded by a
health professional after a vaccination is administered. For this
study, copies of paper-based forms or printouts of digital vaccina-
tions records obtained from study participants were manually
inspected and the number and date(s) of TBE immunization were
recorded.
2.3.2. Self-reported questionnaire
The questionnaire consisted of four questions. Participants were
asked to 1) Report whether they or someone that they know had
experienced tick-related health problems; 2) Their frequency of
episodes of time spent in nature, during tick season; 3) Self-
estimation of the risk of contracting TBE; and 4) Reasons for
abstaining from vaccination (in the event that they were not vacci-
nated for TBE). Completed questionnaires were manually inspected
and responses recorded.
2.3.3. Statistical analyses
Prior to analysis, data were post-stratified according to age and
gender. Vaccination coverage among study participants was calcu-
lated at national, large region (Supplementary Table 1) and can-
tonal levels by dose counting. Descriptive statistics with 95%
confidence intervals (mean) were calculated for primary and boos-
ter vaccination coverage. Demographic variables and differences
between groups were evaluated using Pearson chi-square test for
categorical variables and Wilcoxon-Mann-Whitney test for contin-
uous variables using R version 3.6.1 (R Foundation for Statistical
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Computing, Vienna, Austria). Correlations between vaccination
coverage and average disease incidence were performed using
GraphPad Prism version 8.0 (GraphPad Software, Inc., San Diego,
CA) and Pearson correlation coefficients calculated for each pair
using a two-tailed test. Multiple logistic regression analysis evalu-
ating the association between age, gender or questionnaire vari-
ables with the probability of being vaccinated at 1 and 3 doses
was performed and Crude and Adjusted Odds Ratios (OR) with
95% confidence intervals were calculated using R version 3.6.1.
For analysis of variables in the questionnaire, differences between
groups were further evaluated using Pearson chi-square test with
the Rao-Scott correction. For all analyses p-values 0.05 were con-
sidered as statistically significant.
2.4. Estimation of TBE incidence among unvaccinated and vaccine
effectiveness
We estimated TBE incidence among unvaccinated adults for the
study year 2018 taking the percentage of participants with 3 + vac-
cine doses as ‘‘vaccinated” and using adult (18–79) TBE case num-
bers from mandatory disease reporting data [6]. As case number
data are not available by age group at the cantonal level, we esti-
mated values based on national data where 92% of cases occur in
adults [6]. As data for vaccine failure in TBE cases are not publicly
available, we used a value of 4% for the vaccine failure rate based
on a previous study of TBE cases in Switzerland from 2005 to
2011 [5].
2.5. Estimation of population-level protection
We estimated the percentage of the adult population ‘‘pro-
tected” from TBE infection based on immunization dates from vac-
cination records. We defined ‘‘protected” as having completed the
primary series of 3 TBE vaccinations within the last 10 years or
having completed the primary series and at least one booster vac-
cination within the last 10 years.
2.6. Ethical considerations
With each mailing, a letter was included explaining the study’s
procedures and objectives. Participation in the survey was volun-
tary and individuals had the possibility to withdraw submitted
data at any time. Submission of the vaccination records and/or
completed questionnaires were taken as informed consent. Data
were treated confidentially and anonymized prior to analysis.
The study was approved by the Office of Data Protection as well
as the Ethics Committee of the Canton of Zurich.
3. Results
3.1. Participation
Of 26,880 randomly selected individuals, 8,448 (31%)
responded. Individuals submitting only a questionnaire without a
vaccination record (3,713, 14%) or a vaccination record without a
completed questionnaire (256, 1%) were excluded from further
analysis (Fig. 1). A total of 4,479 individuals (17%, Fig. 1, Table 1)
submitted both a completed questionnaire and vaccination record
and were included for analysis. For simplicity, we will henceforth
refer to these individuals as ‘‘participants” or ‘‘respondents”. 18%
of invited females and 15% of invited males participated. In total,
just under 51% of participants were male (Table 1). Participation
by age group was 15% for those 18–39, 17% for those 40–59 and
18% for those 60–79 (Table 1). Participants tended to be older in
comparison to the adult population of Switzerland (Table 1).
Regionally, participation was highest in East Switzerland and low-
est in Ticino (20 and 11% of contacted individuals, respectively,
Table 1).
3.2. Primary vaccination coverage
Among participants, national TBE vaccination coverage was 42%
for one dose but only 33% for a complete primary series of three
doses (n = 4479, Table 2). Vaccination coverage was slightly higher
among men than among women for one dose (46% vs 37%,
p < 0.001) but comparable for 3 doses (34% vs 32%, p = 0.17). Sim-
ilarly, coverage at one dose was higher among those from 18 to 39
(49%) compared to those aged 40–59 (37%) or 60–79 (37%)
(p < 0.001), but comparable at three doses where coverage was
35%, 31% and 32% (p = 0.17), respectively (Table 2).
We observed that vaccination with at least 1 (59%) and 2 (56%)
dose(s) was higher among males aged 18–39 than for any other
age/gender group. Coverage with at least 3 doses (37%), however,
was only slightly greater than for other age/gender groups
(Table 2).
At the large region level, TBE vaccination coverage ranged from
14% (Ticino region) to 60% (Zurich region) for one dose and 8%
(Ticino region) to 50% (Zurich region) for a series of 3 doses
(Fig. 3, Supplementary Table 2). At the cantonal level coverage ran-
ged from 2% (Geneva) to 72% (Thurgau) at one dose and 0 (Geneva)
Table 1
Participant Demographics by Age and Region.
Region Total Switz.* (Adults 18–79) Sample Size (n) Participants (n) Response (%sample size)
Overall 6,570,644 26,880 4,479 16.7
Sex % Switz. % Participants
Male 3,282,778 50.0 14,790§ 2,270 15.3 50.7
Female 3,287,866 50.0 12,009§ 2,209 18.4 49.3
Age Groups % Switz. % Participants
18–39 2,447,156 37.2 8,960 1,339 14.9 29.9
40–59 2,486,310 37.8 8,960 1,552 17.3 34.7
60–79 1,637,178 24.9 8,960 1,588 17.7 35.5
Large Region % Switz. % Participants
Lake Geneva 1,251,746 19.1 3,840 473 12.3 10.6
Ticino 272,375 4.1 3,840 420 10.9 9.4
Midland Switzerland 1,440,871 21.9 3,840 708 18.4 15.8
Northwest Switzerland 895,062 13.6 3,840 667 17.4 14.9
Central Switzerland 627,917 9.6 3,840 721 18.8 16.1
East Switzerland 907,600 13.8 3,840 756 19.7 16.9
Zurich 1,175,073 17.9 3,840 734 19.1 16.4
*2018 Population data from Swiss Federal Statistical Office.
§ 81 Individuals of Unknown Gender.
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to 68% (Uri) at 3 doses (Supplementary Figs. 1 and 2, Supplemen-
tary Table 3). Coverage at  3 doses exceeded half of the adult pop-
ulation in only two cantons (Supplementary Figs. 1 and 2,
Supplementary Table 3). There was a significant, positive correla-
tion (p < 0.001) between average TBE incidence by canton
(2009–2018) and TBE vaccine coverage at both 1 and 3 doses
(Fig. 2). Mean vaccination coverage (at 1 dose, p < 0.001, and 3
doses p < 0.01) was higher in areas overlapping with TBE risk areas
where vaccination was recommended by the FOPH as of 2018
(Supplementary Figs. 1 and 2).
3.3. Booster vaccination coverage
We found that TBE booster vaccination coverage (defined here
as 4 + vaccinations) for adults 18–79 years was 9.5% of the overall
population (Table 2 and Fig. 4). When evaluated as the percentage
of individuals having previously completed the primary series of 3
vaccine doses, we found that 31% of adults 18–79 had received at
least one booster vaccination and that coverage was higher among
older adults 60–79 compared to younger adults aged 18–39 (36%
versus 27%, respectively ((p < 0.01)), with the highest coverage
found among male seniors (41%).
At the large region level, booster vaccine coverage (4 + vaccina-
tions) among participants was highest in Zurich (17%) and lowest
in Lake Geneva (2%) and Ticino (2%) (Fig. 4, Supplementary Table 2).
In general, booster coverage was greater in regions with increased
TBE incidence with the exception of Central Switzerland (Fig. 4).
When evaluating booster coverage by canton, Thurgau and Glarus
had the highest coverage (24% and 23% of participants, Supplemen-
tary Fig. 3, Supplementary Table 3) and Geneva, Jura and Appenzell
Innerrhoden had the lowest coverage (0% for all three). We found
that there was a significant, positive correlation between average
TBE incidence by canton (2009–2018) and TBE booster vaccine
coverage (r = 0.545, p < 0.01, Supplementary Fig. 4).
3.4. Estimation of TBE incidence among unvaccinated adults
Based on vaccination coverage levels among study participants,
we estimated 2018 TBE incidence among unvaccinated adults at
the national level to be 6.83 cases/100,000 compared to 4.37
cases/100,000 [6] for all individuals (Table 3). At the cantonal level
estimates for incidence among unvaccinated adults varied widely,
ranging from no cases in Basel Land to a high of 90.07
cases/100,000 in canton Uri (Supplementary Table 4). According
to these estimates, 16, rather than 10 cantons exceeded the WHO
definition of a ‘‘highly endemic” area (5.0 cases/100,000 individ-
uals) [7], representing just over 60% of the adult (18–79) popula-
tion of Switzerland (Supplementary Table 3, Supplementary
Table 4).
3.5. Estimation of prevented TBE cases and vaccine Effectiveness
Based on our estimate for national TBE incidence among unvac-
cinated adults, we further estimated that 112–162 TBE cases were
prevented among adults 18–79 in 2018 (Table 3). Furthermore,
from these values we calculated 90.9–92.0% Vaccine Effectiveness
(Table 3).
3.6. Estimation of Population-Level protection
We next estimated the percentage of the adult population in
Switzerland ‘‘protected” from TBE infection based on ‘‘current”
immunization. We found that, at the national level, 23% of partic-
ipants submitting vaccination records had received 3 or more TBE
vaccine doses within the last 10 years. Of individuals with at least
one booster vaccination, 84% had received this booster within the
last 10 years.
3.7. Vaccination coverage by TBE awareness and perceived risk
We further explored whether previous experience with tick-
borne illness or perceived risk of illness might impact TBE vaccine
compliance. Participants reporting that they, or someone they
know, had experienced such problems were significantly more
Fig. 1. Flow Chart of Study Respondents - A total of 26,880 requests for
participation were sent to randomly selected individuals by mail. Individuals were
included in the study if the submitted both a questionnaire and a vaccination card.
Table 2
TBE Vaccination Coverage at the National Level.
 1 Dose (95% CI)  2 Doses (95% CI)  3 Doses (95% CI)  4 Doses Total* (95% CI)  4 Doses Primary§ (95% CI)
All Ages 41.7% (40.1–43.3%) 39.9% (38.3–41.5%) 32.9% (31.3–34.5%) 9.5% (8.5–10.6%) 31.3% (29.3–33.0%)
Male 46.0% (43.7–48.3%) 43.7% (41.3–46.1%) 34.0% (31.6–36.4%) 10.0% (8.5–11.6%) 31.9% (27.2–37.0%)
Female 37.4% (35.3–39.6% 36.1% (33.9–38.3%) 31.8% (29.7–33.9%) 9.0% (7.8–10.4%) 28.6% (23.8–33.8%)
18–39 49.3% (46.3–52.4%) 46.9% (43.7–50.0%) 34.7% (31.5–38.0%) 8.6% (6.8–10.7%) 27.1% (23.7–30.8%)
Male 58.8% (54.4–63.1%) 55.8% (51.1–60.4%) 37.4% (32.5–42.5%) 8.8% (6.1–12.3%) 25.2% (20.3–30.7%)
Female 39.6% (35.4–43.9%) 37.6% (33.4–42.0%) 31.9% (27.9–36.1%) 8.4% (6.2–11.0%) 28.8% (23.9–34.0%)
40–59 37.0% (34.5–39.5%) 35.6% (33.2–38.1%) 31.3% (29.0–33.8%) 9.5% (8.0–11.1%) 29.3% (26.0–32.9%)
Male 38.9% (35.1–42.9%) 37.2% (33.4–41.1%) 32.0% (28.4–35.8%) 9.4% (7.2–11.9%) 29.3% (24.4–34.7%)
Female 35.0% (31.9–38.3%) 34.0% (31.0–37.2%) 30.7% (27.7–33.8%) 9.6% (7.6–11.9%) 29.3% (24.8–34.2%)
60–79 37.4% (34.9–39.8%) 35.9% (33.5–38.4%) 32.4% (30.1–34.8%) 11.0% (9.5–12.6%) 36.2% (32.8–39.6%)
Male 36.8% (33.9–39.9%) 34.8% (31.9–37.9%) 31.7% (28.8–34.6%) 12.9% (11.0–15.1%) 41.2% (36.8–45.6%)
Female 37.8% (34.0–41.8%) 36.9% (33.1–40.9%) 33.1% (29.4–37.0%) 9.2% (7.0–11.8%) 27.8% (22.7–33.2%)
* Percentage of participants (n = 4,479)
§ Percentage of participants which have completed the primary series of 3 doses (n = 1,473)
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likely to have received at least one dose of TBE vaccine (46% vacci-
nated who reported yes versus 37% vaccinated who reported no,
Adjusted OR 1.2, Fig. 5, Table 4). Participants that reported being
in nature 4 + times per month between the months of April and
October (peak tick season) were significantly more likely to have
received at least one dose of TBE vaccine (45% of individuals,
Adjusted OR 1.7) compared to those reporting 1–3 nature days
per month (29%) or being in nature ‘‘almost never” (21%). Addition-
ally, participants reporting their perceived risk of contracting TBE
to be ‘‘high” were significantly more likely to have received at least
one dose of TBE vaccine (78% of individuals, Adjusted OR 12.7)
compared to those who perceived their risk to be ‘‘middle” (50%)
or ‘‘low” (22%) (Fig. 5, Table 4).
We additionally evaluated reasons for abstaining from TBE vac-
cination by asking participants to indicate which reason(s) had
prevented them from being vaccinated: 1) at low risk; 2) not
enough information about TBE; 3) not enough knowledge about
the vaccine; 4) sceptical of vaccines in general; 5) not enough time;
or 6) vaccine too expensive. We found that 43% of respondents
listed ‘‘at low-risk” as a reason for abstaining from TBE vaccination.
Fig. 2. Vaccination Coverage versus Average TBE Incidence by Canton - Average TBE
incidence by canton was determined for the period between 2009 and 2018 and
plotted against the percentage of respondents in each canton vaccinated with at
least 1 or at least 3 doses of TBE vaccine. Pearson correlation coefficients were
calculated for each pair using a two-tailed test. For 1 dose - Pearson r = 0.73,








Fig. 3. Map of TBE Vaccination Coverage by Region - The percentage of respondents from each Swiss large region (Table 1) receiving at least 1 (top panel) or at least 3 (bottom
panel) doses of TBE vaccine are shown.
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40% of respondents listed ‘‘not enough information about TBE” and
32% of respondents listed ‘‘not enough knowledge about the vac-
cine”. A further 32% listed that they were ‘‘sceptical of vaccines
in general”. Approximately 9% and 3% of individuals listed ‘‘not
enough time” or ‘‘vaccine too expensive”, respectively (Fig. 6).
4. Discussion
4.1. TBE vaccination coverage at the national level
In this nationwide, cross-sectional study we found that just
over 40% of adult participants living in Switzerland have received
at least 1 TBE vaccine dose, and that just under one-third have
received at least 3 doses – thought to be necessary for establishing
lasting immunity. In comparison, in Austria, which has the highest
TBE vaccination rate in Europe, nearly 90% of the population has
received at least one vaccine dose and nearly 60% have completed
the primary series of 3 doses. Since the initiation of widespread
vaccination campaigns in Austria in the early 1980s, annual disease
incidence has declined substantially. Between 2000 and 2006
Table 3
Estimated TBE Incidence Among Unvaccinated Adultsand Vaccine Effectiveness, 2018.
Estimate 95% Confidence
Interval
TBE Cases 18–79 (Ctot) [6] 314 –
TBE Vaccine Failure Rate (Vfr) [5] 4.0% –
Fraction Population with 3 + TBE Doses
(PPV)
32.9% 31.3–34.5%
Adult (18–79) Population, 2018 (P)* 6,570,644 –
Incidence Among Unvaccinated (Iuv)** 6.83/
100,000
5.97–7.81/100,000
Prevented Fraction in Population (PFpv)
§ 30.1% 28.6–31.6%
Prevented Cases in Population (PC)§§ 135 112–162
Vaccine Effectiveness (VE)# 91.5% 90.9–92.0%
*2018 Population data from Swiss Federal Statistical Office
**Incidence Among Unvaccinated calculated as: Iuv = (Ctot * (1 - Vfr)) / ((1 - PPV) * P)
and reported per 100,000 individuals
* Population data from Swiss Federal Statistical Office
** Incidence Among Unvaccinated calculated as: Iuv = (Ctot * (1 - Vfr)) / ((1 - PPV) * P)
and reported per 100,000 individuals
§ Prevented Fraction in Population calculated as: PFpv = (((Iuv - (Ctot / P)) / Iuv)
§§ Prevented Cases in Population calculated as: PC = P * Iuv * PFpv
# Vaccine Effectiveness calculated as: VE = PFpv / PPV
Fig. 4. TBE Booster Vaccination by Region - The left y axis shows the percentage of
respondents in each Swiss large region having received at least one TBE booster
vaccination (defined at 4 + vaccinations); the right y axis shows the average TBE
disease incidence between 2009 and 2018 in each Swiss large region.
Table 4
Probabilities (Odds Ratio/Adjusted Odds Ratio) for Being Vaccinated with at Least 1 or 3 Doses of TBE Vaccine.
Crude Odds Ratio (95% CI) Adjusted Odds Ratio (95% CI)
 1 Dose  3 Doses  1 Dose  3 Doses
Gender
Male 1.28 (1.13–1.43) 1.13 (1.00–1.27) Ref Ref
Female 0.78 (0.70–0.88) 0.89 (0.79–1.00) 0.58 (0.50–0.68) 0.79 (0.67–0.93)
Age Group
18–39 1.19 (1.04–1.35) 0.93 (0.81–1.06) Ref Ref
40–59 0.81 (0.71–0.91) 0.88 (0.78–0.99) 0.52 (0.43–0.63) 0.79 (0.65–0.97)
60–79 1.05 (0.93–1.19) 1.21 (1.07–1.37) 0.50 (0.41–0.60) 0.79 (0.64–0.96)
Experience with Tick-Related Health Problems
Yes 1.78 (1.58–2.01) 1.92 (1.69–2.18) 1.21 (1.02–1.42) 1.32 (1.11–1.57)
No 0.56 (0.50–0.63) 0.52 (0.46–0.59) Ref Ref
Time Spent in Nature
Almost Never 0.27 (0.17–0.43) 0.26 (0.15–4.45) Ref Ref
1–3 Times/Month 0.43 (0.36–0.52) 0.41 (0.34–0.50) 1.04 (0.53–2.05) 0.95 (0.46–1.99)
4 + Times/Month 2.58 (2.18–3.06) 2.68 (2.23–3.23) 1.72 (0.91–3.28) 1.50 (0.74–3.02)
Self-Perceived TBE Risk
High 7.01 (5.72–8.60) 6.24 (5.18–7.51) 12.65 (9.48–16.88) 11.09 (8.46–14.53)
Middle 1.99 (1.76–2.24) 1.86 (1.64–2.11) 3.38 (2.82–4.04) 3.57 (2.92–4.36)
Low 0.17 (0.15–0.20) 0.16 (0.14–0.19) Ref Ref
Fig. 5. Self-Reported Risk Factors and TBE Vaccination Status - Individuals were
asked whether they or someone that the know had experienced tick-related health
problems (yes or no), the amount of time that they spent in nature between April
and October (almost never, 1–3 times a month or 4 + times a month), and what they
perceived their personal risk of contracting TBE to be (low, medium, high). For each
response, the percentage of individuals receiving at least 1 dose of TBE vaccine is
indicated. For each question indicated on the y axis, frequencies of expected versus
observed values were compared by Pearson’s v2 test using the Rao & Scott
adjustment. ** = p < 0.01 for each comparison.
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alone, TBE vaccination in Austria was estimated to have prevented
2800 cases of illness and 20 deaths [15–17]. In contrast, in Switzer-
land, annual TBE incidence has continued to increase over the last
decades, despite vaccination efforts.
4.2. Demographic differences
When considering demographics, we found that coverage at 1
and 2 doses was significantly higher amongmales aged 18–39 than
for other age/gender groups. In Switzerland, an 18-week military
service is compulsory for young males and vaccinations are pro-
vided as part of basic training. During this time individuals could
potentially receive the first two TBE immunizations. This could
explain the increased vaccination coverage in this group for doses
1 and 2, but not dose 3, which is given 5–12 months after the
second.
While individuals between the ages of 60 and 79 have the high-
est average disease incidence in Switzerland, vaccination coverage
was not significantly higher among study participants in this age
group compared to younger individuals, who have a substantially
reduced disease incidence. In an Austrian study, vaccination rates
tended to be lower in individuals  60 compared to those 16–49
and 50–59 [16], while, in contrast, two Swedish studies demon-
strated that those  60–65 tended to be better vaccinated than
younger adults and children [18,19] These conflicting findings sug-
gest that, despite increased risk, age is not necessarily a consistent
driver of TBE vaccination.
4.3. Regional variation
We further found that vaccination coverage varied widely
throughout Switzerland with coverage at the cantonal level rang-
ing from approximately 8–70% and approximately 14–60% at the
large region level. In both cases, coverage was higher in areas
where vaccination was recommended for residents (as of 2018)
by the FOPH due to TBE risk. There was a significant correlation
between average TBE incidence and TBE vaccination coverage by
canton at both  1 and  3 doses. These findings support the idea
that FOPH recommendations, as well as potentially increased TBE
awareness among healthcare providers, the public, or both, help
to promote vaccine uptake. A follow-up study to investigate the
influence of the recent 2019 change in national TBE vaccination
recommendations on vaccination uptake is warranted, especially
with the further rise in reported TBE cases in 2020 [6]. Importantly,
while national policy changes impact TBE vaccine uptake, cantonal
differences in the implementation of these policies could be a
source of variability in coverage. For example, 21 of 26 cantons
permit vaccination in pharmacies, and only 19 of these offer TBE
vaccination [20].
4.4. TBE incidence among Unvaccinated, prevented Cases, and vaccine
Effectiveness
It is further worth noting that TBE incidence, both at the
national and cantonal levels, has continued to increase despite vac-
cination efforts, suggesting that immunization based on risk areas
alone may not be enough to protect from disease. We estimated
2018 TBE incidence among unvaccinated adults at 6.83
cases/100,000 compared to 4.37 cases/100,000 for all (vaccinated
and unvaccinated) individuals. We further estimated that, as a
result of vaccination, 112–162 TBE cases were prevented among
adults 18–79 in Switzerland in 2018 alone. Although our analysis
was not comprehensive, and we did not have access to raw case
data and, therefore needed to make several assumptions, we esti-
mated Vaccine Effectiveness at 90.9–92.0%, which is in line with
the more systematic analysis performed by Heinz et al [17]. At
the cantonal level we found that 16, rather than 10, cantons
exceeded the WHO definition of a ‘‘highly endemic” area (5.0
cases/100,000 individuals), representing more than 60% of the
adult population. Together, these findings indicate that many indi-
viduals remain at risk for TBE and that substantially more adults
should be vaccinated in order to reduce disease incidence.
4.5. Population-Level protection
While we found that vaccination coverage is higher in endemic
areas, coverage at  3 doses exceeded half of the adult population
in only two cantons suggesting that a large proportion of the pop-
ulation remains susceptible to TBE, even in areas where TBE is a
significant risk. When we considered whether participants were
‘‘current” for TBE vaccination, we found that less than one-
quarter met these criteria and could be assumed to have protective
immunity. For comparison, just over 40% of the population resides
in the 10 cantons that, in 2018, fell within the WHO definition of a
‘‘highly endemic” area and just over 80% of the population resides
in the 17 cantons with known TBE-endemic areas (and FOPH TBE
vaccination recommendations as of 2018) [6,12].
4.6. Impact of disease perceptions and attitudes
Of the three areas examining perception and knowledge that
might influence TBE vaccination uptake, we found that risk percep-
tion was the most significantly correlated, with participants
reporting a ‘‘high” perceived risk of contracting TBE nearly 13
times more likely to have received at least one dose of TBE vaccine
compared to those who estimated their risk to be ‘‘middle” or
‘‘low”. Furthermore, low risk perception, along with lack of knowl-
edge, was cited as the most frequent reason for not getting a TBE
vaccination. In a recent survey conducted in 11 European coun-
Fig. 6. Self-Reported Reasons for Abstaining from TBE Vaccination - From a list of
possibilities (x axis) individuals who had not been vaccinated for TBE (as confirmed
by vaccination card) were asked to indicate why they had not been vaccinated with
more than one answer possible. Percentages of individuals indicating each response
are given.
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tries, the strongest motivators for TBE vaccination were fear of dis-
ease (38%) and residence or time spent in high-risk areas (31–35%),
while vaccination coverage studies in Sweden found an increased
likelihood of being vaccinated among those reporting  2 weeks
of outdoor exposure in known risk areas or frequent visits to for-
ests or other areas with TBE risk [16,19,21]. In the same studies,
the major reasons for not receiving vaccination were the beliefs
that vaccination was unnecessary (33%), that there was no risk of
contracting disease (23%) [16] and lack of perceived risk (29%)
[19]. However, more individuals listed lack of time (23%) and vac-
cine expense (26%) as reasons for not being vaccinated compared
to in our study (9 and 3%, respectively) [19]. Although cost does
not appear to be a major factor in not receiving TBE vaccination
in Switzerland at the national level, this effect may vary by region
as vaccine costs are only reimbursed by compulsory health insur-
ance in FOPH-recommended areas. Taken together, these findings
support the positive impact of awareness of health consequences
and risk perceptions and behaviours on TBE vaccination and com-
pliance, suggesting that public health interventions promoting
such knowledge might be beneficial in improving vaccine compli-
ance not only in Switzerland, but also in countries searching for
methods to combat the same problem.
5. Limitations
An important limitation in this study was the participation rate.
Approximately 17% of contacted individuals submitted both a
completed questionnaire and a vaccination record, which is low,
but not unusual for a study design based on response by mail.
While we obtained a high enough response rate to evaluate cover-
age at the regional level (as per our study design), responses were
not sufficient to extend all analyses to the cantonal level. Further-
more, participation was highest among individuals aged 60–79
(35.5%, Table 1) although this group represents the smallest por-
tion of the adult Swiss population (24.9%). Similarly, participation
was lowest in those 18–39 (29.9% of adults) although this group
is nearly as large as those 40–59 (37.2% of adults), demographically
speaking. To adjust for this, data were post-stratified prior to anal-
ysis. Moreover, although the sampling frame used is comprehen-
sive, it is not exhaustive and there were inaccuracies in the list
of addresses used to contact individuals based on household move-
ment, deaths, etc. Approximately 3% of the letters were returned as
‘‘undeliverable” suggesting that this represents a relatively small
fraction of the overall sample.
Such a study design also comes with the risk that individuals
interested in a topic are more likely to participate. It is possible
that individuals that have been vaccinated for TBE, those having
some previous knowledge of TBE disease, or those with increased
risk due to occupation or other exposure to ticks, were more likely
to participate than those that have not been vaccinated, were not
aware of illness caused be TBEV, or who had a lower risk of expo-
sure. In this case, vaccination coverage would appear artificially
high, as would the frequency of individuals reporting some previ-
ous knowledge of TBE or tick-borne disease. From a separate anal-
ysis of the complete set of 8,192 questionnaires that we received,
we found that individuals reporting that they had not been vacci-
nated were more likely to not submit a vaccination card, compared
to individuals who did report being vaccinated (data not shown).
Similarly, the percentage of individuals reporting via questionnaire
that they had been vaccinated was lower among those submitting
only a questionnaire compared to those submitting both a ques-
tionnaire and a vaccination record (35% versus 42%, data not
shown), indicate some level of bias in our study. Moreover, the
use of an incentive to increase participation may have introduced
an additional bias.
A further limitation of this study is that the use of a cross-
sectional design allows only correlations, but no causal effects to
be determined. A nationwide vaccination registry would be ideal
for rapid and accurate assessment of vaccination uptake. Unfortu-
nately, such a representative registry is not yet available in
Switzerland. Consequently, personal vaccination records are cur-
rently used to collect and evaluate vaccination data. However,
despite being completed by healthcare providers, vaccination
records may contain errors, or they may be incomplete (i.e. if an
individual does not bring their record to a vaccination appointment
or update it afterward). Regarding our estimation of protection
from TBE, as we did not collect serum to evaluate TBEV antibody
titres, we could only estimate protection based on vaccination his-
tory, assuming that 3 doses were and boosters at appropriate inter-
vals where necessary and sufficient for seropersistence (Reviewed
in [22]).
6. Conclusions
Vaccination coverage in Switzerland is highly variable between
regions, highlighting the impact of heterogeneous disease inci-
dence and corresponding heterogeneous vaccination recommen-
dations and implementations at the cantonal level. Despite the
trend toward increasing disease incidence over the last decades,
only a third of adults in Switzerland have completed the primary
TBE vaccination series. Public health interventions focusing on
awareness of health consequences and risk perceptions and beha-
viours will be effective in improving TBE vaccination coverage.
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